BTK
Gli inibitori della tirosina chinasi di Bruton (BTK) sono composti che mirano specificamente a inibire la BTK, un enzima cruciale coinvolto nella segnalazione del recettore delle cellule B e nella regolazione dell'angiogenesi. La BTK svolge un ruolo significativo nella proliferazione e nella sopravvivenza delle cellule cancerose, in particolare nelle malignità ematologiche. Inibendo la BTK, questi composti possono interrompere l'angiogenesi e la crescita tumorale, rendendoli preziosi nella terapia del cancro. Presso CymitQuimica, offriamo una gamma di inibitori della BTK di alta qualità per supportare la tua ricerca in oncologia, immunologia e angiogenesi.
Trovati 165 prodotti di "BTK"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ARQ 531
CAS:ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.Formula:C25H23ClN4O4Purezza:98.68% - 99.63%Colore e forma:SolidPeso molecolare:478.93AS-1763
CAS:AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Formula:C33H31FN6O3Purezza:≥95%Colore e forma:SolidPeso molecolare:578.64Orelabrutinib
CAS:Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).Formula:C26H25N3O3Purezza:97.77% - 99.54%Colore e forma:SolidPeso molecolare:427.49Ref: TM-T12317
1mg86,00€5mg177,00€10mg299,00€25mg492,00€50mg682,00€100mg897,00€500mg1.791,00€1mL*10mM (DMSO)205,00€Tirabrutinib hydrochloride
CAS:Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Formula:C25H23ClN6O3Purezza:99.27% - 99.95%Colore e forma:SolidPeso molecolare:490.94Rilzabrutinib
CAS:Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).Formula:C36H40FN9O3Purezza:98.28% - 99.76%Colore e forma:SolidPeso molecolare:665.76Ref: TM-T12542
1mg99,00€5mg235,00€10mg376,00€25mg655,00€50mg944,00€100mg1.320,00€500mg2.642,00€1mL*10mM (DMSO)344,00€MT-802
CAS:MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Formula:C41H41N9O8Purezza:95.93% - 97%Colore e forma:SolidPeso molecolare:787.82Ref: TM-T16157
1mg92,00€5mg177,00€10mg269,00€25mg510,00€50mg692,00€100mg888,00€200mg1.251,00€1mL*10mM (DMSO)231,00€Btk inhibitor 2
CAS:Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Formula:C24H25N5O3Purezza:99.94%Colore e forma:SolidPeso molecolare:431.49Ref: TM-T10629
1mg34,00€2mg49,00€5mg74,00€10mg98,00€25mg215,00€50mg356,00€100mg434,00€1mL*10mM (DMSO)82,00€IBT6A
CAS:IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Formula:C22H22N6OPurezza:99.8% - 99.88%Colore e forma:SolidPeso molecolare:386.45SJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Formula:C41H45ClN8O7Purezza:98%Colore e forma:SolidPeso molecolare:797.3FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Colore e forma:LiquidDD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formula:C55H62N10O8Colore e forma:SolidPeso molecolare:991.163BTK-IN-5
CAS:BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Formula:C23H32N4O5Colore e forma:SolidPeso molecolare:444.532GBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Formula:C44H47N9O6Purezza:98%Colore e forma:SolidPeso molecolare:797.9TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Colore e forma:Odour SolidNRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Formula:C43H51N11O6Colore e forma:SolidPeso molecolare:817.94PTD10
CAS:PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.Formula:C49H51N11O8Purezza:99.12%Colore e forma:SolidPeso molecolare:922Ref: TM-T79201
1mgPrezzo su richiesta5mg540,00€10mgPrezzo su richiesta25mgPrezzo su richiesta50mg1.730,00€100mgPrezzo su richiestaPROTAC BTK Degrader-1
CAS:Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.
Formula:C43H43N9O4Colore e forma:SolidPeso molecolare:749.86BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Colore e forma:Odour SolidBRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formula:C23H23ClFN7O2Colore e forma:SolidPeso molecolare:483.93Tyrosinase-IN-16
CAS:Tyrosinase-IN-16 inhibited tyrosinase.Formula:C8H6BrN3SPurezza:99.94%Colore e forma:SolidPeso molecolare:256.12
